and central nervous system injury, [5] [6] [7] and may accelerate the decline in kidney function and worsen glomerulosclerosis in cats with CKD. 8, 9 Furthermore, HT is known to exacerbate proteinuria, a negative prognostic indicator in cats with CKD. 10 Several factors likely contribute to the pathogenesis of HT in cats.
In people, impaired renal sodium handling, excessive activation of the renin-angiotensin-aldosterone system (RAAS), sympathetic nervous system hyperactivity, and endothelial dysfunction, among other factors, may contribute to HT of renal origin. 11 Results of clinical trials have identified the beneficial renoprotective and cardioprotective effects of RAAS blockade in people, which highlights the importance of the RAAS in HT development. [12] [13] [14] The role of the circulating RAAS has been investigated in hypertensive cats with naturally occurring [15] [16] [17] [18] and experimentally-induced 19, 20 CKD, hyperthyroidism, 21 and idiopathic hypertension. 18 Hyperactivity of the RAAS has been identified in some, but not all, cases.
Drugs that inhibit the RAAS, including angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs), may be prescribed for their antihypertensive effects. The ARBs selectively antagonize the angiotensin II, subtype-1 (AT 1 ) receptor, which mediates the pathologic effects of the RAAS's major effector, angiotensin II. These effects include vasoconstriction, intravascular volume expansion, and sympathetic nervous system activation, as well as induction of pro-inflammatory and profibrotic pathways and oxidative stress, among other factors. 22 Telmisartan is a nonpeptide ARB used for the control of HT and cardiovascular protection in human patients. In a preclinical study of healthy cats, telmisartan more effectively attenuated the angiotensin I-induced increase in systolic arterial blood pressure (SBP) than did benazepril, losartan, irbesartan, and placebo, suggesting a potential advantage for the treatment of cardiovascular and renal diseases in this species. 23 In a separate study, telmisartan treatment was associated with measurable decreases in indirectly measured SBP in awake, unstimulated cats. 24 Most recently, the results of a large, double-blind, randomized clinical trial in Europe showed that, compared to placebo, daily PO administered telmisartan was associated with a significantly greater decrease in SBP (−19 ± 22.0 mm Hg versus −9 ± 17.7 mm Hg, respectively) after 14 days of treatment. 25 Our objectives were to evaluate the safety and efficacy of PO administered telmisartan solution for decreasing SBP in cats with spontaneous HT. It was hypothesized that compared to placebo, daily telmisartan treatment would be associated with a significant and clinically relevant decrease in SBP within 28 days, that this effect would persist over a 6-month treatment period, and that drug administration would be safe over the same period.
| MATERIALS AND METHODS

| Trial design
This study was a 28-day multicenter, prospective, randomized (2 : 1), double-blind, placebo-controlled, parallel group trial, followed by a
154-day open-label extended-use telmisartan phase, carried out according to the guidelines of Good Clinical Practice. 26 and urine culture. Screening abdominal radiographic and ultrasonographic examinations were performed at the discretion of the attending clinician.
| Animals
| Trial medications
Telmisartan solution (4 mg/mL) or an equivalent volume of visually identical placebo was administered PO at a dosage of 1.5 mg/kg q12h for 14 days, followed by 2 mg/kg PO q24h. These dosages were based on the results of a previous dose-finding study in normal cats, which identified the most effective decrease in SBP at dosages >2 mg/kg/day. 24 Trial medication was administered by the owners, who maintained daily logs that were monitored at re-evaluations. At each visit, trial drug dose was recalculated based on contemporaneous body weight. 
| Indirect BP determination
| Randomization and allocation
For each trial site, cats were block randomized to treatment group based on order of enrollment, using blocks of 3 with a ratio of 2:1 (telmisartan : placebo). Randomization tables were generated by the trial sponsor using a computer software program (SAS version 9.2; SAS FIGURE 1 Overview of trial design. Bloodwork, complete blood count, and serum biochemical analyses; SBP, systolic arterial blood pressure measurement; UA, urinalysis; UC, urine culture; UPC, urinary protein-to-creatinine ratio Institute Inc., Cary, North Carolina). Treatment assignment was performed using a web-based, secure, electronic data capture system (VISION; Prelude Dynamics, LLC, Austin, Texas). For cases from a given trial site to be considered in the final analysis, the site must had ≥2 evaluable cats per treatment group. No more than 40% of the total number of enrolled cases could be contributed by a single study site.
| Blinding
Cat owners, trial monitors, participating veterinarians, and personnel participating in the clinical management of cases and samples were blinded to treatment assignment. Study drugs were prepared by the sponsor and provided directly to each study site with no further product preparation required. During the 28-day efficacy period, treatment assignment was disclosed only if necessary for the evaluation, treatment, or both of an adverse event; if such an event occurred before day 28 ± 2, the animal was removed from the trial. To determine the cat's eligibility for the extended-use phase of the trial, unblinding also occurred after a cat completed the entire 28-day efficacy period and the owner approved participation.
| Populations considered
Cats that were randomized and received at least 1 dose of trial medication comprised the intention-to-treat population. Cats that successfully fulfilled all trial eligibility criteria, had analyzable data available from at least the first scheduled visit (day 14 ± 2) and that adhered to the trial protocol with no major deviations, comprised the per-protocol population. Cats were designated according to concurrent disease as belonging to 1 of 4 subpopulations: CKD, hyperthyroidism, CKD and hyperthyroidism, or idiopathic HT; these designations were used for descriptive purposes only.
| Primary outcome variables
The primary outcome variables with respect to efficacy were change in SBP from baseline to day 14 ± 2 and from baseline to day 28 ± 2, calculated by subtracting baseline SBP from SBP at the time point of interest.
A composite primary efficacy end point, defined a priori, was evaluated in the per-protocol population. First, to be considered effective, the magnitude of SBP decrease from baseline to day 14 ± 2 had to be significantly larger in the telmisartan as compared to placebo-treated group.
Second, to establish clinical relevance, the magnitude of decrease in SBP from baseline to day 28 ± 2 must have been >20 mm Hg in the telmisartan-treated group. This threshold for clinical relevance was chosen to ensure a decrease in category of risk for future TOD regardless of baseline SBP, as advocated by the American College of Veterinary Internal Medicine consensus statement. 27 The composite primary efficacy end point also was evaluated in the intention-to-treat population. Adverse events were defined as any unfavorable or unintended observation that occurred after the use of trial medication, regardless of whether it was considered product-related. Adverse events were recorded and classified according to accepted guidelines. 29 In addition to conventional serious adverse events (eg, death, severe injury), hypotension associated with clinical signs or requiring removal from the trial, and development or worsening of renal, cardiac, ocular, or central nervous system TOD, were considered serious adverse events for the purposes of this trial.
| Secondary outcome variables
| Statistical methods
Commercial software was used for all statistical analyses (SAS version 9.2; SAS Institute Inc). Sample size was calculated by simulations that used estimates of SBP decrease variability and assumed that placeboand telmisartan-treated cats would experience SBP decreases of 0 and 18 mm Hg, respectively. These estimates were based on data generated in a study of normal cats. 24 Simulations conducted at 30 trial sites, each with 4 telmisartan-and 2 placebo-treated cats, indicated a power of at least 80% to detect a significant difference in SBP decrease between treatment groups, with an alpha level of 5%.
Analyses with respect to the composite primary efficacy end point and for the secondary outcomes of changes in laboratory variables were carried out by comparing treatment groups in the per-protocol population. The primary efficacy end point also was evaluated in the intention-to-treat population.
Change in SBP from baseline to day 14 was performed using a were similar between treatment groups in both the intention-to-treat and per-protocol populations. Any observed differences were small and considered clinically irrelevant ( at the day 14 ± 2 visit was 52.1% in the telmisartan-treated group and 19.0% in the placebo-treated group (Table 2) . Data from telmisartan-treated cats included in the 6-month extended-use period are also shown. Data are presented as mean ± SD, median (range), or number (%). Abbreviations: CKD, chronic kidney disease; IRIS, International Renal Interest Society; SBP, systolic arterial blood pressure.
FIGURE 3
Mean (95% confidence interval) systolic arterial blood pressure (A) and change in systolic arterial blood pressure compared to baseline (B) in cats treated with telmisartan or placebo (per-protocol population) during the blinded efficacy period
Mean change in SBP from baseline to day 14 ± 2 is presented for the 4 clinical subpopulations in Table 3 and for cats stratified according to baseline SBP in Table 4 . More cats belonging to the hyperthyroidism subpopulation were allocated to receive telmisartan than predicted by the 2 : 1 telmisartan : placebo randomization ratio. Because this trial was not adequately powered to detect differences in BP responses among subpopulations, these data are presented for descriptive purposes only. Table 2 .
Mean values for laboratory variables measured at baseline and on day 28 ± 2 were similar between treatment groups. Any observed differences were small and remained within laboratory reference ranges (Table 5) . No clinically relevant differences in change of any laboratory variable between baseline and day 28 ± 2 were noted between treatment groups. Mean values for laboratory variables at trial end (day 182 ± 2) in the telmisartan-treated group also were similar to those noted at baseline and day 28 ± 2 and remained within laboratory ref- 25 In a previous study undertaken in hypertensive Abbreviation: SBP, systolic arterial blood pressure. *Per-protocol population. As noted in the text, direct comparison of response rates at day 28 should be done cautiously given the disproportionate and relatively high rate (in the placebo-treated group) of removal after day 14 due to SBP >180 mm Hg.
TABLE 3
Mean ± SD change in SBP from baseline to day 14 ± 2 for spontaneously hypertensive cats enrolled in the present study (perprotocol population), classified according to concurrent disease cats, a similar BP decrease also was seen after 14 days of amlodipine treatment at a dosage of 0.125 mg/kg q24h. 
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Of the RAAS-modifying drugs available, ACEi have been the most extensively studied in cats. 20, 31, 35, 36 However, reports involving clinically hypertensive cats describe generally inadequate antihypertensive efficacy of ACEi. 3, 15, 17 Possible explanations for this failure may include administration of inappropriately low dosages or failure of these drugs to completely antagonize angiotensin II production.
Because of their specificity for the AT 1 receptor, ARBs have a mechanistic advantage over ACEi, because the former preserve the beneficial counter-effects associated with stimulation of angiotensin II subtype-2 receptors. This specificity also allows ARBs to antagonize the detrimental effects of angiotensin II independent of its source, circumventing ACE-independent proteolytic pathways that may contribute to persistent angiotensin II production during treatment with ACEi (ie, "angiotensin breakthrough"). 22 In a recent prospective Urinary protein-to-creatinine ratio 0. registration study of cats with naturally occurring CKD, treatment with telmisartan, but not benazepril, was associated with a statistically significant decrease in UPC at all studied time points, suggesting a valuable role for the former in these patients. 33 During the 28-day efficacy period of the present trial, persistence of a mean decrease in SBP was documented not only for telmisartantreated cats but also, to a significantly lesser extent, for placebo- In the present trial, the percentage of cats classified as "responders"
(ie, those for which SBP decrease to <150 mm Hg, or by at least 15% of baseline, was documented) at the day 14 ± 2 visit was 52.1% in telmisartan-treated cats and 19.0% in placebo-treated cats. The 52.1% response rate in telmisartan-treated cats is comparable to the 46% response rate noted after 14 days in amlodipine-treated hypertensive cats in a previous randomized, double-blinded, placebocontrolled study. 28 At subsequent visits, response rates noted in telmisartan-treated cats ranged from 52.5% to 71.7% (Table 2) .
However, direct comparison of response rates noted in this trial versus those reported previously 28 should be made with caution beyond trial day 14 ± 2 because of differences in trial protocol. For example, escalation (ie, doubling) of study drug dosage was allowed after day 14 in cats classified as nonresponders in the previous study, an adjustment that was performed in 54%. 28 In contrast, dose escalation was not allowed in the present trial. Instead, cats for which SBP >180 mm Hg was noted on or after day 14 were removed from the trial. In addition, at the day 14 ± 2 visit, a decrease in the total daily dose of telmisartan, from 1.5 mg/kg q12h to 2 mg/kg q24h, was Our study had some limitations. Because it was considered unethical to withhold antihypertensive treatment in these patients, cats with SBP >200 mm Hg or with evidence of severe TOD were excluded. Therefore, the efficacy of telmisartan in this subset of patients remains to be further investigated. However, when stratified according to baseline SBP, the mean magnitude of SBP decrease at the day 14 ± 2 visit was numerically higher in more severely hypertensive cats (ie, those with SBP of 180-200 mm Hg) compared to those with less severe hypertension (ie, those with SBP of 160-179.9 mm Hg), suggesting that telmisartan treatment would be expected to produce equal, if not larger, decreases in SBP in cats with SBP >200 mm Hg (Table 4) . In a recent case report, after amlodipine had to be withdrawn because of development of gingival hyperplasia, telmisartan as monotherapy effectively controlled severe hypertension in a cat, whereas benazepril alone was unsuccessful. 38 Finally, because cats with severe renal azotemia were excluded from the present trial, the efficacy and safety of telmisartan treatment in these cats also was not evaluated. As discussed above, telmisartan dosage rates exceeding 2 mg/kg/day in the maintenance phase were not studied. In conclusion, telmisartan oral solution, administered at the dosage studied here, safely and effectively decreased SBP in hypertensive cats. The clinically relevant magnitude and duration of decreased SBP, combined with previously documented beneficial effects on the RAAS system in cats with CKD, make this drug a potentially valuable treatment for cats with systemic HT.
